BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Prestige Biopharma Reports Phase 3 Success For HD204 Demonstrating Clinical Equivalence In Advanced NSCLC

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung can...

March 25, 2026 | News

Dizal Reports ZEGFROVY Achieves Superior Progression Free Survival In Phase 3 WU KONG28 Trial For EGFR Exon20ins NSCLC

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over pla...

March 23, 2026 | News

Alphamab Oncology Doses First Patient In Global Phase I Trial Of First PD L1 VEGFR2 Bispecific ADC

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101...

March 18, 2026 | News

Alphamab Oncology IND For Dual Payload Bispecific ADC JSKN021 Accepted By China NMPA

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative du...

March 16, 2026 | News

Vaxcellbio And Reber Genetics Form Strategic Partnership To Expand Companion Animal Immunotherapy Across Asia

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced on Wednesday that it has signed a Master Partnership Agreement (MPA) wi...

March 12, 2026 | News

Leads Biolabs Doses First Patient In Phase II Trial Of PD L1 4 1BB Bispecific Antibody For Esophageal Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has bee...

March 10, 2026 | News

Servier To Acquire Day One Biopharmaceuticals For $2.5 Billion To Strengthen Rare Oncology Pipeline

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with...

March 09, 2026 | News

Pfizer And Astellas Report Strong Phase III EV 304 Results For PADCEV Plus Pembrolizumab In MIBC

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with ove...

March 02, 2026 | News

Optellum Secures TGA Approval In Australia For AI Powered Virtual Nodule Clinic

Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration ...

March 02, 2026 | News

WuXi XDC And Earendil Labs Forge Strategic Alliance To Advance Next Generation AI Designed ADCs

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializin...

March 02, 2026 | News

Japan Approves Alpha DaRT To Expand Treatment Options In Head And Neck Cancer

Offering a New Option for Head and Neck Cancer Treatment HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor tr...

February 27, 2026 | News

Astellas And Vir Biotechnology Forge Global Partnership To Advance VIR 5500 In Prostate Cancer

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commerci...

February 25, 2026 | News

Etherna And Almirall Advance LAD116 mRNA LNP Therapy Into IND Enabling Studies For Non Melanoma Skin Cancer

etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one o...

February 25, 2026 | News

CStone Secures UK MHRA Approval For Sugemalimab In Stage III Non Small Cell Lung Cancer

Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products...

February 24, 2026 | News

Stay Connected